Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Eastern Cooperative Oncology Group
Ludwig Institute for Cancer Research
University of California, San Francisco
University of Illinois at Chicago
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
University of Chicago